Endocrine Abstracts

Introduction: Tumor-induced osteomalacia (TIO) is a paraneoplastic syndrome due to an overproduction of fibroblast growth factor 23 (FGF23) by small and benign mesenchimal tumors. FGF23 increase causes hypophosphatemia, osteomalacia and muscle weakness. TIO is usually cured by tumour resection, but neoplasms may be unidentifiable/unresectable or the patient may refuse surgery. In these cases, medical treatment with high doses of oral phosphate and calcitriol is mandatory, even...

Introduction: Thalassaemia syndromes are a group of inherited haemolytic disorders determining chronic anaemia, iron overload and organ damage (through the production of ROS), necessitating of iron chelation therapy. Nowadays, there is scant knowledge on hypercalciuria in thalassaemic Western patients. Therefore, aim of our study was evaluating the prevalence of hypercalciuria and identifying risk factors and clinical consequences associated with its development.<p class="...

Introduction: Patients with transfusion-dependent β-thalassemia (TDT) frequently exhibit elevated urinary calcium excretion, contributing to kidney stone formation and osteoporosis. The underlying mechanism of hypercalciuria in β-thalassemia remains elusive, with FGF23 playing a potential role. FGF23, a bone-derived hormone, primarily acts on the kidneys by inhibiting phosphate reabsorption in the proximal tubules while enhancing calcium uptake in the distal tubules....

Introduction: Thyroid nodules (TN) may display somatic RAS mutations, that, however, lack of diagnostic value. In our experience, somatic RAS mutation evaluation could be useful since it has a very high negative predictive value. In the past, somatic RAS mutation had been associated with a good prognosis in thyroid cancer.Objective: This study aims to evaluate whether somatic RAS mutation may associate with TN differential growth pattern.<p class="ab...

Background: Patients with transfusion-dependent β -thalassemia (TDT) often experience several endocrine complications, including diabetes mellitus (DM). In TDT, the reliability of glycated haemoglobin (HbA1c) assessment is compromised due to elevated erythrocytes turnover and frequent transfusions. Glycated Albumin (GA), a product of non-enzymatic albumin glycation, has been investigated as a medium-term glycaemic marker (21 days) in the general diabetic population. Since...